

Central Pain Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/CE7EA6198089EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: CE7EA6198089EN

Abstracts

The 7 major central pain syndrome markets reached a value of US\$ 5.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 8.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.

The central pain syndrome market has been comprehensively analyzed in IMARC's new report titled "Central Pain Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Central pain syndrome is a neurological disorder characterized by persistent and debilitating pain that results from damage or dysfunction within the central nervous system. The pain associated with this condition is often described as a constant burning, aching, or stabbing sensation, and it may be localized to specific areas or affect larger regions of the body. Individuals suffering from the disorder may experience muscle stiffness, tingling, weakness, numbness, etc. This symptom can have a significant impact on a patient's quality of life, causing physical and emotional distress, sleep disturbances, depression, and anxiety. The diagnosis of central pain syndrome can be challenging, as there are no specific tests that can definitively confirm the disease. A healthcare professional will initially perform a thorough evaluation of clinical features and medical history, along with a comprehensive neurological examination. Additionally, numerous other imaging tests, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are utilized to identify structural abnormalities or lesions in the brain that could be contributing to the pain.

The rising cases of stroke, which can disrupt the blood flow to the brain, resulting in tissue damage, are primarily driving the central pain syndrome market. In addition to this, the increasing incidences of various associated risk factors, including trauma,

infection, chronic stress, obesity, depression, etc., are also propelling the market growth. Furthermore, the widespread adoption of effective drugs, such as antidepressants, anticonvulsants, opioids, etc., to alleviate the pain and manage other symptoms related to the ailment is creating a positive outlook for the market. Besides this, the escalating popularity of non-pharmacological interventions, like physical and occupational therapies, that aim to improve daily functioning and promote independence in patients is also bolstering the market growth. Additionally, the emerging application of transcutaneous electrical nerve stimulation techniques, since they work by activating the nerves and interfering with pain signals, is acting as another significant growth-inducing factor. Moreover, the inflating demand for intrathecal drug delivery systems, owing to their numerous benefits over other oral or systemic medications, such as reduced side effects as well as enhanced convenience and compliance, is expected to drive the central pain syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the central pain syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for central pain syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the central pain syndrome market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the central pain syndrome market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the central pain syndrome market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current central pain syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the central pain syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the central pain syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the central pain syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of central pain syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of central pain syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of central pain syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with central pain syndrome across the seven major markets?

What is the size of the central pain syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of central pain syndrome?

What will be the growth rate of patients across the seven major markets?

Central Pain Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for central pain syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the central pain syndrome market?

What are the key regulatory events related to the central pain syndrome market?

What is the structure of clinical trial landscape by status related to the central pain

syndrome market?

What is the structure of clinical trial landscape by phase related to the central pain syndrome market?

What is the structure of clinical trial landscape by route of administration related to the central pain syndrome market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CENTRAL PAIN SYNDROME - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CENTRAL PAIN SYNDROME - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CENTRAL PAIN SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 CENTRAL PAIN SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CENTRAL PAIN SYNDROME - UNMET NEEDS

10 CENTRAL PAIN SYNDROME - KEY ENDPOINTS OF TREATMENT

11 CENTRAL PAIN SYNDROME - MARKETED PRODUCTS

- 11.1 List of Central Pain Syndrome Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 CENTRAL PAIN SYNDROME - PIPELINE DRUGS

12.1 List of Central Pain Syndrome Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. CENTRAL PAIN SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CENTRAL PAIN SYNDROME – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 CENTRAL PAIN SYNDROME - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Central Pain Syndrome - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Central Pain Syndrome - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Central Pain Syndrome - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Central Pain Syndrome - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Central Pain Syndrome - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Central Pain Syndrome - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Central Pain Syndrome - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Central Pain Syndrome - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Central Pain Syndrome - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Central Pain Syndrome - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Central Pain Syndrome - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Central Pain Syndrome - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Central Pain Syndrome - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Central Pain Syndrome - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Central Pain Syndrome - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Central Pain Syndrome - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Central Pain Syndrome - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Central Pain Syndrome - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Central Pain Syndrome - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Central Pain Syndrome - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Central Pain Syndrome - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Central Pain Syndrome - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Central Pain Syndrome - Access and Reimbursement Overview

16 CENTRAL PAIN SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CENTRAL PAIN SYNDROME MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CENTRAL PAIN SYNDROME MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Central Pain Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/CE7EA6198089EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE7EA6198089EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

